Association of distant tumor metastasis with the presence of anti-Hu antibody in peripheral blood of NSCLC patients
Article
Figures
Metrics
Preview PDF
Reference
Related
Cited by
Materials
Abstract:
Objective : To investigate the clinical pathological features of patients with non-small cell lung cancer who had anti-Hu antibody and whether the presence of the antibody is associated with distant metastasis of the tumor. Methods: Peripheral blood samples were collected from 75 NSCLC patients enrolled into the Department of Oncology between June and December of 2013, and from 100 healthy volunteers who did not have tumor or neurologic history and underwent blood test between November and December of 2013 in the Clinical laboratory, General Hospital, Jinan Command of the People’s Liberation Army. Anti-Hu antibody was measured by ELISA. Clinical pathological features investigated include sex, age, pathological type, differentiation stage, EGFR mutation, tumor markers (CEA, CY21-1, and NSE), and distant metastasis. Results: Compared with healthy volunteers, NSCLC patients had significantly elevated anti-Hu antibody titration (40.00±35.76 ng/ml vs 16.40±8.19 ng/ml, P<0.01). The increase of the anti-Hu antibody was significantly associated with brain metastasis (81.81% vs 50.00%, P=0.015), but not distant metastasis to other tissues. It was also independent of sex, age, gender, pathological stage, EGFR mutation, and the levels of CEA and NSE (all P>005). Multivariate regression analysis further indicated that increased anti-Hu antibody level was an independent variable for brain metastasis prediction (P=0.015). Conclusion: Peripheral blood anti-Hu antibody is increased in NSCLC patients and is associated with brain metastasis of the tumor, which deserves further investigation to understand the mechanism.
Keywords:
Project Supported:
Project supported by the National Natural Science Foundation of China (No.30901788; No.81272619)